ALUR
Allurion Technologies Inc.1.5400
+0.0200+1.32%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
18.88MP/E (TTM)
-Basic EPS (TTM)
-16.20Dividend Yield
0%Recent Filings
8-K
Board shrinks amid resignation
Allurion Technologies' board shrank to eight members on September 30, 2025, after director Milena Alberti-Perez resigned to pursue media sector opportunities, including a new public company board seat. Her exit from the Audit Committee chair role stemmed from no disagreements, aiming to boost efficiency and cut compensation costs. The board now evaluates a successor. Smaller boards streamline decisions.
10-Q
Q2 FY2025 results
Allurion Technologies posted Q2 revenue of $3.4M, down 71% y/y from $11.8M amid distributor shifts and a temporary French sales suspension, yet gross margins held at 74% versus 76% last year. Operating loss narrowed to $7.0M from $9.3M y/y, thanks to 64% cuts in sales and marketing and 58% in R&D, while net loss widened to $9.3M from $8.3M due to $4.5M fair-value hits on convertible notes. Cash dipped to $12.7M, with $43.0M RTW notes outstanding at 6% and $42.4M revenue financing liability; free cash flow not disclosed in the 10-Q. Q2 diluted EPS of -$1.28 aligns with 7.3M shares. France sales resumed in February 2025 post-ANSM clearance. Restructuring risks loom from workforce cuts.
8-K
Financial restatements announced
Allurion Technologies' audit committee determined on August 14, 2025, that prior financial statements from 2023 through Q1 2025 can't be trusted due to errors in fair value accounting for its February 2023 revenue interest financing agreement and $48.0 million April 2024 convertible notes. These non-cash misstatements hit other comprehensive income, other income/expense, and net income but spare revenue, margins, expenses, and cash flows. Restatements loom for the 10-K and Q1 10-Q, while prior quarters fold into the annual fix. Controls falter amid known weaknesses. Delays risk delisting.
8-K
Allurion Q2 revenue dips amid pivot
Allurion Technologies reported Q2 2025 revenue of $3.4 million, down from $11.8 million last year, due to distributor transitions and sales suspension in France, yet operating expenses dropped 48% year-over-year, narrowing the operating loss to $7.0 million from $9.3 million. The company pivoted to low-dose GLP-1 combination therapy, signed a term sheet with a strategic partner for manufacturing and R&D, and saw its PMA application for the Allurion Balloon accepted by the FDA. A potential non-cash miscalculation in fair value accounting may require restating prior financials, but won't affect revenue or cash.
8-K
Allurion pivots to GLP-1 combos
Allurion Technologies unveiled a strategic pivot on August 5, 2025, emphasizing low-dose GLP-1 combination therapy, muscle mass preservation, and U.S. entry, alongside a workforce cut of 65% to streamline costs. Preliminary Q2 results show $3 million revenue and $7 million operating loss, improved from $9.3 million last year via 50% expense reductions, though distributor shifts disrupt sales. Signed term sheet with partner for GLP-1 balloon development; FDA accepted PMA for balloon. Restructuring incurs $1.5 million in severance. Short-term turbulence looms.
AEMD
Aethlon Medical, Inc.
2.94-0.11
AIRS
AirSculpt Technologies, Inc.
2.57-0.06
ALNT
Allient Inc.
54.64-0.39
ALRTF
ALR Technologies SG LTD.
0.02-0.00
MDT
Medtronic plc.
97.72-0.85
MGRM
Monogram Technologies Inc.
6.00+0.00
NVCR
NovoCure Limited
12.93-0.04
NXL
Nexalin Technology, Inc.
0.81-0.01
RBOT
Vicarious Surgical Inc.
2.43-0.04
TCRT
Alaunos Therapeutics, Inc.
4.36+0.09